Carmine Gentile – VJRegenMed

Addressing challenges in cardiac tissue engineering

Simon Ng — Mon, 17 Jan 2022 13:05:28 +0000

Transplantation is the current solution for patients with heart failure, but can result in organ rejection and requires immunosuppressive medication. Carmine Gentile, PharmD/PhD, FAHA, University of Technology Sydney, Sydney, Australia, comments on remaining barriers to successfully developing tissue engineered tissue for cardiovascular disease. Replicating the vascular network of the heart, as well the contractile force of the host cardiac tissue remains a challenge for researchers. Dr Gentile additionally highlights clinical translation issues associated with tissue engineering. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Bioprinting highlights at TERMIS 2021

Simon Ng — Mon, 17 Jan 2022 13:05:27 +0000

Carmine Gentile, PharmD/PhD, FAHA, University of Technology Sydney, Sydney, Australia, shares his highlights in the field of bioprinting at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021). Dr Gentile describes how current innovations in biofabricating tissues have enabled lower production costs, increasing the accessibility of technologies such as 3D printing to researchers, which will ultimately drive further progress in the field. This interview took place at TERMIS 2021.

Vascular network formation within 3D bioprinted cardiac tissue

Simon Ng — Tue, 11 Jan 2022 17:26:18 +0000

Carmine Gentile, PharmD/PhD, FAHA, University of Technology Sydney, Sydney, Australia, describes research on replicating the vasculature within heart tissues. Bioengineered cardiac tissues are a promising therapy for patients who have heart failure, and developing a functioning vasculature is vital for these patients. Research on bioinks and stem cell-derived heart tissues have enabled to develop in vitro cardiac models. Dr Gentile additionally emphasizes the requirement for a multidisciplinary approach within the field, with experts across different specialties needed to successfully develop and transplant tissue engineered cardiac tissue. This interview took place at 6th world congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).